Lung Cancer
Volume 62, Issue 1 , Pages 85-91 , October 2008

Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC

  • Lars Henrik Jensen

      Affiliations

    • Department of Oncology, Vejle Hospital, DK-7100 Vejle, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 7940 6000; fax: +45 7940 6907.
    • ,
  • Kell Osterlind

      Affiliations

    • Department of Oncology, Herlev University Hospital, DK-2730 Herlev, Denmark
    • ,
  • Carsten Rytter

      Affiliations

    • Department of Oncology, Vejle Hospital, DK-7100 Vejle, Denmark

Received 5 December 2007 ,Revised 3 February 2008 ,Accepted 14 February 2008.

References 

  1. Chabner BA, Roberts TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72
  2. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35(12):1505–1509
  3. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001;12(11):1643–1649
  4. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol. 2001;12(10):1375–1381
  5. Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol. 2001;12(12):1677–1681
  6. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf. 2005;4(5):915–928
  7. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330–353
  8. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006;130(4):1211–1219
  9. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001;6(Suppl. 4):12–16
  10. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64(9 Suppl 5):S4–S7
  11. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110–115
  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216
  13. Pfeiffer P, Mortensen JP, Bjerregaard B, Eckhoff L, Schonnemann K, Sandberg E, et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer. 2006;42(16):2738–2743
  14. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17(2):239–245
  15. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38(3):349–358
  16. Lima AP, del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl). 2005;14(2):151–154
  17. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–661
  18. Viele CS. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm. 2007;64(9 Suppl. 5):S25–S32
  19. Bartel SB. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm. 2007;64(9 Suppl. 5):S8–S14
  20. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(19):3852–3859
  21. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–857
  22. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007;57(3):348–358
  23. O’Brien ME, Szczesna A, Karnicka H, Zatloukal P, Eisen T, Hartmann W, et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol. 2004;15(6):921–927

PII: S0169-5002(08)00071-8

doi: 10.1016/j.lungcan.2008.02.009

Lung Cancer
Volume 62, Issue 1 , Pages 85-91 , October 2008

Article Tools

* Image Usage & Resolution